The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Recent advances in the discovery of flavonoids and analogs with high‐affinity binding to P‐glycoprotein responsible for cancer cell multidrug resistance
Abstract
P‐glycoprotein (P‐gp) is a plasma membrane glycoprotein that confers multidrug resistance on cells by virtue of its ability to exclude cytotoxic drugs in an ATP‐dependent manner. The most commonly considered hypothesis is that P‐gp acts as an ATP‐driven drug‐export pump, the mechanism of which is not understood in detail. Therefore, a tremendous effort is being made to find out modulator molecules to inhibit P‐gp. We have been developing flavonoid derivatives as a new class of promising modulators using a new in vitro rational‐screening assay based on measurements of the binding‐affinity toward the C‐terminal nucleotide‐binding domain (NBD2) of P‐gp. This review is focused on our results obtained with a variety of flavonoids. Structure–activity relationships of flavonoids as potential MDR modulators are reported. © 2002 Wiley Periodicals, Inc. Med Res Rev, 22, No. 5, 512–529, 2002; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/med.10015
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01276.x · Cited by 5,312
Advances in flavonoid research since 1992
Harborne, J. B., & Williams, C. A. (2000) · Phytochemistry · doi:10.1016/s0031-9422(00)00235-1 · Cited by 3,956
Cited by
Halliwell, B. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.01.028 · Cited by 759
Halliwell, B., Rafter, J., & Jenner, A. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.1.268s · Cited by 711
Flavonoid permeability across an in situ model of the blood–brain barrier
Youdim, K. A., Qaiser, M. Z., Begley, D. J., Rice-Evans, C. A., & Abbott, N. J. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.11.023 · Cited by 603
Flavonoids as prospective compounds for anti-cancer therapy
Ravishankar, D., Rajora, A. K., Greco, F., & Osborn, H. M. I. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.10.004 · Cited by 572
Bioavailability enhancers of herbal origin: An overview
Kesarwani, K., & Gupta, R. (2013) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(13)60060-x · Cited by 498
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Flavonoid–drug interactions: Effects of flavonoids on ABC transporters
Morris, M. E., & Zhang, S. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.003 · Cited by 273
Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance
Xiao, H., Zheng, Y., Ma, L., Tian, L., & Sun, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648407 · Cited by 263
HENDRICH, A. B. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00238.x · Cited by 261
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Gonzales, G. B., Smagghe, G., Grootaert, C., Zotti, M., Raes, K., & Camp, J. V. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.1003649 · Cited by 254
Metadata
- Authors
- Boumendjel, A., Di Pietro, A., Dumontet, C., & Barron, D.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2002-07-30
- Volume
- 22
- Issue
- 5
- Pages
- 512-529
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2133228174
- Cited by
- 162
- References
- 2
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.